Mr Saransh Chaudhary’s Gain Spotlight in Pharma Media
Mr. Saransh Chaudhary features in two leading pharmaceutical publications, sharing perspectives on intelligent manufacturing and regulatory readiness for India's MSME pharma industry.
Bringing industry perspectives to the forefront, Mr. Saransh Chaudhary, Executive Director of Venus Remedies Limited and CEO of Venus Medicine Research Centre, has earned recognition in leading pharmaceutical publications for his insights on the evolving pharmaceutical landscape.
His recent articles in Pharmabiz and Pharmaceutical Ingredients Review explore two key aspects of India's pharmaceutical future: using technology to make smarter manufacturing decisions and helping smaller manufacturers meet evolving quality standards.
Driving Smarter Pharmaceutical Manufacturing
In his article, Digital Twins Should Start with Decisions on Factory Floor, published in PharmaBiz, Mr Chaudhary explores how digital twin technology can reshape pharmaceutical manufacturing by making production planning more intelligent, responsive, and data-driven.
Rather than treating digital twins as sophisticated dashboards, he emphasizes how they can help manufacturers simulate production scenarios, optimise resource utilisation, anticipate operational constraints, and make informed decisions.
The article also highlights the importance of integrating digital twins with existing ERP systems, maintaining accurate data and ensuring that technology supports human expertise rather than replacing it.
Going beyond technology adoption, the article underlines that successful digital transformation must keep people at the centre, with experienced teams retaining ownership of critical decisions and ensuring that technology translates into measurable operational value.
Addressing the Schedule M Challenge for MSME Pharma
Adding another significant perspective to the industry conversation, Mr. Saransh authored an article in Pharmaceutical Ingredients Review, titled “Can India's MSME Pharma Rise to the Schedule M Challenge?”
The article examines the challenges faced by India's micro, small and medium pharmaceutical enterprises in meeting revised Schedule M requirements. It explores critical barriers, including limited access to capital, infrastructure gaps, shortages of skilled talent, uneven GMP maturity, and the need to strengthen data integrity practices.
Mr Chaudhary stresses that compliance requires more than investments in equipment. It demands a fundamental shift towards a culture of quality, accountability and continuous improvement.
His perspective highlights the need for coordinated industry and policy support to help smaller manufacturers meet global quality expectations. It reinforces that compliance is not merely a regulatory requirement but a culture built on accountability, transparency, and quality.
Strengthening Venus Remedies' Voice in Pharma
Together, these features reflect Mr. Saransh Chaudhary's continued engagement with important conversations shaping the pharmaceutical sector. Besides, such contributions also reinforce Venus Remedies' commitment to innovation, responsible manufacturing and advancing India's pharmaceutical capabilities.
